

References

DWI in cancer prostate

References

1. Allen KS, Kressel HY, Arger PH, et al (1989):Age-related changes of the prostate: evaluation by MR imaging. *AJR*; 152:77-81.
2. Andriole GL, Catalona WJ (1993). Using PSA to screen for prostate cancer: The Washington University experience. *Urol Clin North Am* 1993; 20:647–651
3. Atalar E and Menard C (2005). MR – guided interventions for prostate cancer. *Magn reson Imaging Clin N Am* 2005; 13:491-504.A
4. Ausumilli S. And Pretorius E. (2006):MRI of the prostate gland. In Marcos S. And Cohan R. (Eds), *new techniques in uroradiography*. 2nd ed. Taylor & Francis Group, New York 11; pp265-268.
5. Ayala AG, Ro JY, Babaian R, et al (1989): The prostatic capsule; does it exist? *Am. J. Surg Pathol*; 13:21-27.
6. Baretton GB, Vogt T, Blasenbreu S, Löhns U. Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: an image cytometric study. *Hum Pathol*. 1994 May;25(5):506-13.
7. Beyersdorff D, Taymoorian K, Knosel T. et al (2005):MRI of prostate cancer at 1.5 and 3.0 T: Comparison of image quality in tumor detection and staging. *AJR*; 185: 1214-1220.
8. Berquin M., Min Y., Wu R. et al (2007):Modulation of prostate cancer genetic risk by Omega-3 and Omega-6 fatty acids. *J. Clin. Invest*; 117 (7):1866-1875.

References

9. Bloch BN, Furman-Haran E, Helbich TH, et al (2007):Prostate Cancer: Accurate Determination of Extracapsular Extension with High-Spatial-Resolution Dynamic Contrast-enhanced and T2-weighted MR Imaging—Initial Results. *Radiology*; 245:176–185.
- 10.Bostwick DG & Amin MB (1996):Prostate and seminal vesicles. In: Damjanou Ivan & Linder James (Ed). *Anderson's Pathology*. St. Louis, Missouri, Mosby;p 2200-2230.
- 11.Bostwick DG, Liu L, Brawer MK, Qian J (2004). High-grade prostatic intraepithelial neoplasia. *Rev Urol*. 2004 Fall;6(4):171-9.
- 12.Brown TR, Kincaid BM, Ugurbil K, et al (1982):NMR chemical shift imaging in three dimensions. *Proc Natl. Acad. Sci USA*; 79:3523–3526.
- 13.Buckley DL, Roberts C, Parker GJ, et al (2004): Prostate Cancer: Evaluation of Vascular Characteristics with Dynamic Contrast-enhanced T1-weighted MR Imaging— Initial Experience. *Radiology*; 233:709–715.
- 14.Casciani E, Poletti E, Bertini L, et al (2004):Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. *Radiology Med (Torino)*; 108:530–541.
- 15.Cho JY (2003):Prostate. IN: Seung Hyup Kim (ed). *Radiology, illustrated: Uroradiology*. Philadelphia, Saunders, p571.
- 16.Claus FG, Hricak H, Hattery R, et al (2004):Pretreatment Evaluation of Prostate Cancer: Role of MR Imaging and 1HMR Spectroscopy. *RG*; 24:S167–S180.
- 17.Clinton S (2005):Tomatoes or Lycopene: A role in prostate Carcinogenesis? *J. Nutr*; 135 (8): 2057s-2059s.

References

- 18.Chen AP, Cunningham CH, Kurhanewicz J, et al (2006):High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. *Magn Reson Imaging*; 24(7):825–832.
- 19.Choyke PL, Dwyer AJ, Knopp MV, et al (2003):Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. *J Magn Reson Imaging*; 17:509–520
- 20.Coakly F. And Hricak H. (2000): Radiologic anatomy of the prostate gland: A clinical approach. *Radiology Clin. North. Am*; 38:15-30.
- 21.Coakly F, Eberhardt S, Wei D. et al (2002):Blood loss during radical retropubic prostatectomy:Relationship to morphologic features on preoperative endorectal magnetic resonance imaging. *Urology*; 59: 884-888.
- 22.Coffey D. (1992):The molecular biology and physiology of the prostate and seminal vesicles. In *campbell's urology* 6th ed, (8); 221-237. Philadelphia, London, Toronto, WB, Saunders company.
- 23.Cornud F, Flam T, Chauveinc L, et al (2002):Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. *Radiology*; 224:203–210.
- 24.Daniel M. Cornfeld MD, a, and Jeffrey C. Weinreb MDa (2007): MR Imaging of the Prostate: 1.5T versus 3T ;*Magnetic Resonance Imaging Clinics of North America*, vol.15(2007)pp.433-448.
- 25.De Jong IJ, Pruim J, Elsinga PH, et al (2002);Visualization of prostate cancer with 11C-choline positron emission tomography. *Eur Urology*; 42:18–23.
- 26.Deserno WM, Harisinghani MG, Taupitz M, et al (2004):Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. *Radiology*; 233(2):449– 456.

- 27.Desouza NM, Reinsberg SA, Scurr ED, et al (2007). Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. *Br J Radiol* 2007; 80:90–95
- 28.Dhingsa R, Qayyum A, Coakley F, et al (2004):Prostate cancer localization with Endorectal MR imaging and MR Spectroscopic Imaging: Effect of Clinical Data on reader accuracy. *Radiology*; 230:215-220.
- 29.Egger SE, Scardino PT, Carroll PR, et al (2007):Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. *J Urology*; 178:2260–2267.
- 30.Engelhard H, Hollenbach HP, Deimling M, et al (2000): Combination of signal intensity measurements of lesions in the peripheral zone of the prostate with MRI & serum PSA level for differentiating benign disease from prostatic cancer. *Eur Radiol* 2000; 10:1974-1953.
- 31.Engelbrecht MR, Jager GJ, Laheij RJ, et al (2002): Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. *Eur Radiology*; 12:2294–2302.
- 32.Engelbrecht MR, Huisman HJ, Laheij RJ, et al (2003):Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. *Radiology*; 229:248–254.
- 33.Epestin J, Granan M, Humphry P, et al (1995):Interobserver reproducibility in the diagnosis of PIN. *Am. J. Surg. Path*; 19:873-886. In *Campbell's Urology* 8th ed. Kavouss P, Novick P, Saunders Philadelphia (2002). 3025-3150.
- 34.Epstein JI (2006):What's new in prostate cancer disease assessment in 2006? *Curr Opin Urology*; 16:146–151.

References

35. Erbersdobler A, Augustin H, Schlomm T, et al (2004): Prostate cancers in the transition zone. 1. Pathological aspects. *BJU Int*; 94:1221–1225.
36. Flocks R. (1973): The arterial distribution within the prostate gland, its role in transurethral prostatic resection. *J. Urology*; 73: 524-548.
37. Fütterer J, Engelbrecht MR, Huisman HJ, et al (2005): Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. *Radiology*; 237:541–549.
38. Fütterer J, Heijmink S, Scheenen T, et al (2006): Prostate Cancer Localization with Dynamic Contrast enhanced MR Imaging and Proton MR Spectroscopic Imaging, *Radiology*; 241:449–458.
39. Ganry O. (2005): Phytoestrogen and prostate cancer risk. *Prev. Med*; 41:1-6.
40. Gaudin P, Sesterhenn I, Wojnok J. et al (1997): Incidence and clinical significance of high grade PIN in TRUS specimens. *Urology*; 558-563. In *Campbell's Urology 8th ed.* Kavouss p, Novick P, Saunders Philadelphia (2002). 3025-3150.
41. Graser A, Heuck A, Sommer B, et al (2007): Per-Sextant Localization and Staging of Prostate Cancer: Correlation of Imaging Findings with Whole-Mount Step Section Histopathology. *AJR*; 188:84–90.
42. Haider M, Kwast T, Tanguay J, et al (2007): Combined T2-Weighted and Diffusion-Weighted MRI for Localization of Prostate Cancer, *AJR*; 189:323–328.
43. Haggman M, Macoska J, Wojnok J. et al (1997): The relationship between PIN & PC critical issue. *Urology*; 8: 22-40. In *Campbell's Urology 8th ed.* Kavoss p, Novick P, Saunders Philadelphia (2002). 3025-3150.

References

44. Harisinghani MG, Barentsz J, Hahn PF, et al (2003): Noninvasive detection of clinically occult lymph node metastases in prostate cancer. *N Engl J Med*; 348:2491–2499.
45. Heesakkers R, Fütterer J, Hövels A, et al (2006): Prostate Cancer Evaluated with Ferumoxtran-10-enhanced T2*-weighted MR Imaging at 1.5 and 3.0 T: Early Experience, *Radiology*; 239:481-487.
46. Heijmink S, Fütterer J, Hambrock T, et al (2007): Prostate Cancer: Body-Array versus Endorectal Coil MR Imaging at 3 T—Comparison of Image Quality, Localization, and Staging Performance, *Radiology*; 244:184-195.
47. Hiratsuka J, Jo Y, Yoshida K, et al (2004). Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2004; 59:684–690
48. Hom J, Coakley F, Simko J, et al (2007): High-Grade Prostatic Intraepithelial Neoplasia in Patients with Prostate Cancer: MR and MR Spectroscopic Imaging Features—Initial Experience. *Radiology*; 242:483– 489.
49. Hricak H. (1991): The prostate gland. In Hricak H, Carrington B: *MRI of the pelvis*. London, Martin Dunitz; 249-311.
50. Hricak H, Wang L, Wei DC, et al (2004): The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. *Cancer*; 100:2655–2663.
51. Hricak H., Choyke P., Eberhardt S. et al (2007): Imaging Prostate Cancer: A Multidisciplinary Perspective. *Radiol.*; 243: 28-53.A
52. Huben R and Murphy C (1986): Prostate cancer: An update. *CA*; 36:274-292.

References

53. Huisman HJ, Engelbrecht MR, Borents JO, et al (2001): Accurate estimation of pharmacokinetic contrast enhanced dynamic MRI parameters of prostate. *J Magn Reson Imaging*; 13:607-614.
54. Huzjan R, Sala E, Hricak H, et al (2005): Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer. *Nat Clin Pract Urology*; 2:434–442.
55. Ikonen S, Kivisaari L, Vehmas T, et al (2001): Optimal timing of post-biopsy MR imaging of the prostate. *Acta Radiology*; 42:70–73.
56. Ito H, Kamoi K, Yokoyama K et al (2003): Visualization of prostate cancer using dynamic contrast-enhanced MRI: Comparison with transrectal power Doppler ultrasound. *BJR*; 76:617-624.
57. Inyoung Song, Chan Kyo Kim, Byung Kwan Park, et al (2010). Assessment of Response to Radiotherapy for Prostate Cancer: Value of Diffusion-Weighted MRI at 3 T. *AJR June 2010*; 194:W477-W482
58. Jacobs MA, Ouwerkerk R, Petrowski K, MacUra KJ (2008). Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. *Topics in Magnetic Resonance Imaging*. 2008;19(6):261–272.
59. Jager G, Ruijter E, Van de kaa C. et al (1997): Dynamic Turbo Flash subtraction technique for contrast-enhanced MR Imaging of the prostate: Correlation with histopathologic results. *Radiology*; 203:645-652.
60. Jager G, Severens J and Thornbury J. (2000): Prostate cancer staging: Should MR Imaging be used? A decision analytic approach. *Radiology*; 215:445-451.

References

61. Jemal A, Murray T, Ward E, et al (2005): Cancer statistics, 2005. *CA Cancer J Clin* 2005; 55:10–30.
62. Keetch D, Humphry P, Stahl D. et al (1995): Morphometric analysis and clinical follow up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. *J. Urol*; 154:347-351. In *Campbell's Urology* 8th ed. Kavoussi P, Novick P, Saunders Philadelphia (2002). 3025-3150.
63. Kim CK, Park BK, Han JJ, et al (2007): Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results. *J Comput Assist Tomogr*; 31:449–454.
64. Kirby RS, Christmas TJ, Brawer MK (1996): Epidemiological aspects In: *Prostate Cancer*. London, England: Mosby, 1996, p 23-32.
65. Kikuchi E, Scardino PT, Wheeler TM, et al (2004): Is tumor volume an independent prognostic factor in clinically localized prostate cancer? *J Urology*; 172:508–511.
66. Koh DM, Brown G, Riddell AM, et al (2008): Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. *Eur Radiology*; 18:903–910.
67. Kurhanewicz J, Vigneron DB, Nelson SJ, et al (1995): Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. *Urology*; 45:459–466.
68. Kurhanewicz J, Vigneron DB, Hricak H, et al (1996): Prostate Cancer: Metabolic Response to Cryosurgery as Detected with 3D H-1 MR Spectroscopic Imaging. *Radiology* 1996; 200:489-496.

References

69. Kurhanewicz J, Vigneron DB, Hricak H, et al (1996): Three-dimensional ^1H spectroscopic imaging of the in situ human prostate with high spatial (0.24 to 0.7 cm³) spatial resolution. *Radiology* 1996; 198:795–805.
70. Kurhanewicz J, Vigneron DB, Nelson SJ, et al (2000): Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. *Neoplasia*; 2:166–189.
71. Kurhanewicz J, Vigneron DB, Males DG et al (2000): The prostate: MR imaging & spectroscopy. *Radiol Clin North Am*; 38:115-38.
72. Kurhanewicz J, Swanson M, Nelson SJ, et al (2002): Magnetic resonance molecular imaging of prostate cancer. *J Magn Reson Imaging*; 16:451–463.
73. Kutikov A, Guzzo T and Malkwicz S (2006): Clinical approach to the prostate: An update. *Radiology. Clin. N. Am*; 44:649-663.
74. Kwek JW, Thng CH, Tan PH, et al (2004): Phased-array magnetic resonance imaging of the prostate with correlation to radical prostatectomy specimens: local experience. *Asian J Surg*; 27:219–224.
75. Lee TY, Purdie TG, Stewart E, et al (2003): CT imaging of angiogenesis. *Q J Nucl Med*; 47: 171–187.
76. Lim HK, Kim JK, Kim KA, et al (2009): Prostate Cancer: Apparent Diffusion Coefficient Map with T2-weighted Images for Detection—A Multireader Study. *Radiology*; 250:145–151.

References

77. Lowsley O. (1912): The development of the human prostate gland with reference to the development of other structures at the neck of the urinary bladder. *Am. J. Anatomy*; 13:299-349.
78. Mazaheri Y, Shukla-Dave A, Hricak H, et al (2008). Prostate Cancer: Identification with Combined Diffusion-weighted MR Imaging and 3D 1H MR Spectroscopic Imaging-Correlation with Pathologic Findings, *Radiology* 2008; 246:480–488.
79. Males RG, Vigneron DB, Star-Lack J, et al (2000): Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. *Magn Reson Med*; 43:17–22.
80. Masoom A. Haider, Theodorus H. van der Kwast, et al (2007). Combined T2-Weighted and Diffusion-Weighted MRI for Localization of Prostate Cancer. *AJR* August 2007; 189:323-328
81. Masterson TA, Pettus JA, Middleton RG, et. al (2005): Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pT3b disease by nodal and margin status. *Urology*; 66:152–155.
82. Matlaga BR, Eskew A, McCullough DL, et al (2003): Prostate biopsy: indications and technique. *J Urology*; 169:12–19.
83. McNeal J and Bostwick D (2002): Intraductal dysplasia. A premalignant lesion of prostate. *Humpothal*; 17; 67-71. In *Campbell's Urology* 8th ed. Kavouss P, Novick P, Saunders Philadelphia (2002). 3025-3150.

References

84. Meux MD et al (2002): Imaging In: Carroll PR & Grossfeld GD (eds): American Cancer Society Atlas of Clinical Oncology Prostate Cancer. BC Decker. Ontario, p 119.
85. Moore K (1992): Clinically oriented anatomy Baltimore, Hong Kong, London, Munich, Philadelphia, Sydney, Tokyo. 3rd ed. Williams and Wilkins p.278.
86. Montironi R, Vela-Navarrete R and Lopez-Beltran A (2006): Update on prostate biopsies with cancer. Eur. Urology; 49:441-447.
87. Montanens R (2005): Prognostic parameters other than Gleason score for the daily evaluation of prostate cancer in needle biopsy. Eur. Urology; 49:441-447.
88. McNeal JE (1978): Origin and evolution of benign prostatic enlargement. Invest Urology; 15:340-354.
89. McNeal J (1981): Normal and pathologic anatomy of the prostate. Urology; 17:11-16.
90. McNeal JE (1988): Normal histology of the prostate. Am J Surg Pathol; 12:619-624.
91. Muldon L and Resnick M (1990): Prostatic ultrasonography, Normal anatomy of the prostate, Philadelphia: Decker. 1st ed. Pp33-40.
92. Mullerad M, Hricak H, Kuroiwa K, et al (2005): Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urology 2005; 174:2158–2163.

References

93. Namimoto T, Morishita S, Saitoh R. et al (1998):The value of dynamic MR Imaging for hypointensity lesions of the peripheral zone of the prostate. *Comput. Med. Imaging Graph*; 22:239-245.
94. Nash P, Bruce J, Induhara R. et al (1996):Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. *J. Urology*; 155:607-609.
95. Naya Y and Babaian RJ (2003):The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy. *J Urology*; 170:2306–2310.
96. Noguchi M, Stamey TA, Neal JE, et al (2000):An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. *J Urology*; 163:1751– 1755.
97. Noone TC, Semelka RC et al (2002):Male pelvis. In: Semelka RC (ed). *Abdominal-Pelvic MRI*. Wiley-Liss, New York. P981.
98. Novis D, Zarbo R, Valenstein P et al (1999):Diagnostic uncertainly express prostate needle biopsies a college of American Pathologist, Q- Probes study of 15753 prostate needle biopsies in 332 instultration. *Arch. Pathol. Pab. Med*; 123:687-692.
99. Nunes L, Schiebler M, Rauschning W et al (1995): The normal prostate and periprostatic structures: Correlation between MR Images made with an endorectal coil and cadaveric microtome sections. *AJR*; 164:923-927.
100. Ocak I, Bernardo M, Metzger G, et al (2007):Dynamic Contrast-Enhanced MRI of Prostate Cancer at 3 T: A Study of Pharmacokinetic Parameters. *AJR*; 189:192–201.

References

101. Oelrich T (1983):The urethral sphincter muscle in the male. *Am. J. Anatomy*; 158:229-246.
102. Ogura K, Maekawa S, Okubo K, et al (2001):Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. *Urology* 2001; 57:721-6.
103. Outwater EK, Petersen RO, Siegelman ES, et al (1994):Prostate Carcinoma: Assessment of Diagnostic Criteria for Capsular Penetration on Endorectal Coil MR Images. *Radiology*; 193:333-339.
104. Oyen RH (2003):Dynamic contrast enhanced MRI of the prostate: Is this the way to proceed for characterization of prostatic carcinoma. *Eur Radiology*; 13:921-924.
105. Padhani AR, Nutting CM (2003):Why do we need more accurate intraprostatic location of cancer? *BJR* 76: 585-586.
106. Parivar F, Hricak H et al (1996):Detection of locally recurrent prostate cancer after cryosurgery: Evaluation by transrectal ultrasound, MRI and 3D-MRSI. *Urology* 48(4): 594- 599.
107. Preziosi Paolo, Orlacchio Antonio et al (2003):Enhancement patterns of prostate cancer in dynamic MRI. *Eur Radiology* 13: 925-930.
108. Pels P, Ozturk-Isik E, Swanson MG, et al (2006):Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. *NMR Biomed*; 19:188–197.

References

109. Pieterman RM, Que TH, Elsinga PH, et al (2002): Comparison of (11)C-choline and (18)FFDG PET in primary diagnosis and staging of patients with thoracic cancer. *J Nucl Med*; 43:167–172.
110. Prando A, Kurhanewicz J, Borges A, et al (2005): Prostatic Biopsy Directed with Endorectal MR Spectroscopic Imaging Findings in Patients with Elevated Prostate Specific Antigen Levels and Prior Negative Biopsy Findings: Early Experience. *Radiology*; 236:903–910.
111. Reinsberg S, Payne G, Riches S, et al (2007): Combined Use of Diffusion-Weighted MRI and 1H MR Spectroscopy to Increase Accuracy in Prostate Cancer Detection, *AJR* 2007; 188:91–98.
112. Ren J, Huan Y, Wang H, et al (2008): Diffusion-weighted imaging in normal prostate and differential diagnosis of prostate diseases. *Abdom Imaging*; 33:724–728.
113. Riches SF, Payne GS, Morgan VA, et al (2009). MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. *AJR* 2009; 193:1583–1591
114. Rifkin M (1997): *Ultrasound of the prostate*, 2nd ed. Philadelphia, Lippincott-Raven, 3-14.
115. Rifkin M, Danhert W, Kurtz A. et al (1990): State of the art: Endorectal sonography of the prostate gland. *AJR*; 154:691-700.
116. Rosai J (1996): Male reproductive system: Prostate and seminal vesicles. In: *Ackermans surgical pathology*, 8th ed. St. Louis: Mosby, 1221-1256.

References

117. Rosenkrantz AB, Xiangtian Kong, Benjamin E. Niver, et al (2011). Prostate Cancer: Comparison of Tumor Visibility on Trace Diffusion-Weighted Images and the Apparent Diffusion Coefficient Map. *AJR* January 2011; 196:123-129
118. Salomon L, Colombel M, Patard JJ, et al (1999):Value of ultrasound-guided systematic sextant biopsies in prostate tumor mapping. *Eur Urology*; 35:289–293.
119. Sakr WA, Hass GP, Cassin BJ et al (1993): The frequency of carcinoma & intraepithelial neoplasia of the prostate in young male patients, *J Urology*; 150:379-386.
120. Scardino PT (2005):Continuing refinements in radical prostatectomy: more evidence that technique matters. *J Urology*; 173:338–339.
121. Schiebler ML, McSherry S, Keefe B, et al (1991):Comparison of the digital rectal examination, endorectal ultrasound, and body coil magnetic resonance imaging in the staging of adenocarcinoma of the prostate. *Urol Radiology*; 13:110–118.
122. Schiebler ML, Schnall MD, Pollack HM, et al (1993):Current role of MR imaging in the staging of adenocarcinoma of the prostate. *Radiology*; 189:339-352.
123. Shepherd D, Keetch D, Humphry P, et al (1996):Repeat biopsy strategy in men with isolated PIN in needle biopsy of the prostate. *J. Urol*; 154: 347-351. *Urol*; 8:22-40.
124. Shimofusa R, Fujimoto H, Akamata H, et al (2005):Diffusion-weighted imaging of prostate cancer. *J Comput Assist Tomogr*; 29:149–153.

125. Shimofusa R.(2008): Prostate cancer : Diffusion-Weighted Imaging. In Hayat M.A. (eds). Cancer Imaging Instrumentation and Applications. Elsevier. California; first edition: P 615-8.
126. Shukla-Dave A, Hricak H, Moskowitz C, et al (2007):Detection of Prostate Cancer with MR Spectroscopic Imaging: An Expanded Paradigm Incorporating Polyamines. Radiology; 245:499–506.
127. Siegal JA, Yu E, Brawer MK, et al (1995):Topography of neovascularity in human prostate carcinoma. Cancer; 75:2545–2551.
128. Star-Lack J, Nelson SJ, Kurhanewicz J, et al (1997):Improved water and lipid suppression for 3D PRESS CSI using RF band-selective inversion with gradient dephasing (BASING). Magn Reson Med; 38:311–321.
129. Stamey T and Mcneal J (1992):Adenocarcinoma of the prostate. In campbell’s Urology, 6th ed, vol 2. Philadelphia, WB saunders, PP 1159-1221.
130. Swindle P, McCredie S, Russell P, et al (2003):Pathologic Characterization of Human Prostate Tissue with Proton MR Spectroscopy. Radiology; 228:144–151.
131. Tanaka N, Samma S, Joko M et al (1999):Diagnostic usefulness of endorectal magnetic resonance imaging with dynamic contrast enhancement in patients with localized prostate cancer: mapping studies with biopsy specimens. Int J Urology; 6:593-599.
132. Tanagho E (2002):Anatomy of the lower urinary tract. In campbell’s Urology 8th ed, Philadelphia, WB saunders. 63- 65.
133. Tempany C, RahmouniA, Epestein J, et al (1991):Invasion of the neurovascular bundle by prostate cancer. Evaluation with MR Imaging. Radiology; 181:107-112.

134. Testa C, Schiavina R, Lodi R, et al (2007). Prostate Cancer: Sextant Localization with MR Imaging, MR Spectroscopy, and 11C-Choline PET/CT, *Radiology* 2007; 244:797–806.A
135. Tran TK, Vigneron DB, Sailasuta N, et al (2000):Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. *Magn Reson Med*; 43:23–33.
136. Tsutomu Tamada, Teruki Sone, Yoshimasa Jo, et al (2011). Locally Recurrent Prostate Cancer After High-Dose-Rate Brachytherapy: The Value of Diffusion-Weighted Imaging, Dynamic Contrast-Enhanced MRI, and T2-Weighted Imaging in Localizing Tumors . *AJR* August 2011 197:408-414
137. Vicini FA, Vargas C, Abner A, et al (2005). Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. *J Urol* 2005; 173:1456–1462
138. Vilanova JC, Carles Barceló-Vidal, Josep Comet, et al (2011). Usefulness of Prebiopsy Multifunctional and Morphologic MRI Combined With Free-to-Total Prostate-Specific Antigen Ratio in the Detection of Prostate Cancer *AJR* June 2011; 196:W715-W722
139. Villers A, Mcneal JE et al (1992):Multiple cancers in the prostate: Morphologic features of clinically recognized versus incidental tumors. *Cancer* 70: 2313-2318.
140. Villers A, (1994):Extracapsular tumor extention in PC Monographs in *Urology*; 15 (4):56.
141. Wald LL, Carvajal L, Moyher SE, et al (1996):Phased array detectors and an automated intensity-correction algorithm for high-resolution MR Imaging of the human brain. *Magn Reson Med*; 34:433-439.

142. Wang L, Mullerad M, Hui-Ni Chen, et al (2004):Prostate Cancer: Incremental Value of Endorectal MR Imaging Findings for Prediction of Extracapsular Extension, *Radiology*; 232:133–139.
143. Wang L, Hricak H, Kattan MH, et al (2007):Prediction of Seminal Vesicle Invasion in Prostate Cancer: Incremental Value of Adding Endorectal MR Imaging to the Kattan Nomogram, *Radiology*; 242:182–188.
144. Wang L, Zhang J, Schwartz LH, et al (2007):Incremental Value of Multiplanar Cross-Referencing for Prostate Cancer Staging with Endorectal MRI, *AJR*; 188:99–104.
145. Wang L, Mazaheri Y, Zhang J, et al (2008):Assessment of Biologic Aggressiveness of Prostate Cancer: Correlation of MR Signal Intensity with Gleason Grade after Radical Prostatectomy, *Radiology*; 246:168–176.
146. Wetter A, Engl TA, Nadjmabadi D, et al (2006):Combined MRI and MR Spectroscopy of the Prostate before Radical Prostatectomy. *AJR*; 187:724–730.
147. Wefer AE, Hricak H, Vigneron DB et al (2000):Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and MRSI with step section histology. *J Urology*; 58: 843-848.
148. Westphalen AC, Coakley FV, Qayyum A, et al (2008):Peripheral Zone Prostate Cancer: Accuracy of Different Interpretative Approaches with MR and MR Spectroscopic Imaging. *Radiology*; 246:177–184.
149. Wijkstra H, Wink MH, de la Rosette JJ (2004). Contrast specific imaging in the detection and localization of prostate cancer.*World J Urol*. 2004 Nov;22(5):346-50

References

150. Woodfield CA , Glenn A. Tung, David J. Grand, et al (2010) . Diffusion-Weighted MRI of Peripheral Zone Prostate Cancer: Comparison of Tumor Apparent Diffusion Coefficient With Gleason Score and Percentage of Tumor on Core Biopsy. *AJR* April 2010; 194:W316-W322
151. Wu G, Yu L and Wang L(2006):Application of Gleason analogous grading system and flow cytometry DNA analysis in a novel Knock-in mouse prostate cancer model postgrad. *Med J*; 82 (963):40-45.
152. White S, Hricak E, Forstner O, et al(1995):Prostate Cancer: Effect of Postbiopsy Hemorrhage on Interpretation of MR Images. *Radiology*; 195:385-390.
153. Yeoh E, Russo A, Botten R et al (1998):Acute effects of therapeutic irradiation for prostatic carcinoma on anorectal function. *Gut*; 43:123-127.
154. Yin Y, Ni J, Chen M et al (2007):The therapeutic and preventive effect of RRR- (alpha)- vitamin E succinate on prostate cancer via induction of insulin-Like Groth Factor Binding Protein-3. *Clin. Cance. Res*;l 13(7): 2271-2280.
155. Yuen JSP, Thng CH, Tan PH et al (2004):Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. *J Urology*; 171:1482-1486.
156. Yoshimitsu K, Kiyoshima K, Irie H,et al (2008). Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. *J Magn Reson Imaging*. 2008 Jan;27(1):132-9.
157. Young Jun Choi, Jeong Kon Kim, Namkug Kim, et al (2007). Functional MR Imaging of Prostate Cancer. *Radiographics* January-February 2007; 27:63-75

158. Zakian KL, Eberhardt S, Hricak H, et al (2003):Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging—initial results. *Radiology*; 229:241–247.
159. Zakian KL, Sircar K, Hricak H, et al (2002):Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathology after radical prostatectomy. *Radiology*; 225:628-637.
160. Zakian KL, Sircar K, Hricak H, et al (2005):Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. *Radiology*; 234:804–814.
161. Zech CJ, Herrmann KA, Dietrich O, et al (2008):Black-blood diffusion-weighted EPI acquisition of the liver with parallel imaging: comparison with a standard T2-weighted sequence for detection of focal liver lesions. *Invest Radiology*; 43:261–266.
162. Zelhof B, Pickles M, Liney G, et al (2009). Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. *BJU Int*. 2009; 103:883–888
163. Zhu XP, Li KL, Kamaly-Asl ID, et al (2000):Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging. *J Magn Reson Imaging*; 11:575–585.